Insights On Drug Development

  1. Targeted CRISPR/Cas9 Screen Identifies Superior HEK293 Cell Lines For AAV9 Production 2/5/2025

    In this study, we developed a proprietary clonal suspension-adapted HEK293 cell line (AC001.230) through clonal isolation and high-throughput screening, resulting in improved productivity for 7 out of 10 AAV serotypes compared to 293F cells.

  2. High-Throughput Screen Finds Targets To Boost AAV9 Production In HEK293 Cells 2/5/2025

    Take a look at the potential of this small molecule screening to enhance AAV9 production and improve gene therapy manufacturing efficiency by leveraging novel compounds.

  3. Plasmid Impurity Sizing Of nptII In rAAV By ddPCR 2/5/2025

    Explore our novel ddPCR method for assessing plasmid-derived antibiotic resistance gene impurities in rAAV products to enhance regulatory compliance and ensure the safety and quality of gene therapy vectors.

  4. Method Qualification Of Mass Photometry For The Determination Of Full-To-Empty Capsid Ratio For rAAVs Using The Refeyn System 2/5/2025

    Leverage mass photometry to quickly and accurately monitor the full-to-empty ratio of rAAV samples, ensuring consistent product quality and enhanced safety and efficacy in gene therapy applications.

  5. Quality Over Quantity: Where Is The Trade Off? 2/5/2025

    Our study aims to compare two widely used transfection reagents to our standard process, evaluating their impact on final product quantity and quality as part of our ongoing platform innovation efforts.

  6. Accelerating Innovative Cell Therapy Development Through Phase-Appropriate Potency Control 2/4/2025

    Developing a robust, phase-appropriate potency strategy is essential for ensuring the quality, consistency, and regulatory success of cell and gene therapies.

  7. 5 Trends Impacting CMOs In 2025 2/4/2025

    In 2025, CMOs will navigate Annex 1 compliance, the BioSecure Act’s uncertainty, AI-driven drug development, supply chain challenges from tariffs, and pandemic preparedness strategies.

  8. Advancements In GLP-1 Analog Formulation Development: Overcoming Challenges In Oral Delivery 2/3/2025

    Oral GLP-1 formulations represent a groundbreaking advance in obesity treatment, offering improved patient comfort and adherence while expanding the therapeutic market.

  9. Formulation And Analytical Tour 2/3/2025

    Take a brief tour of Nanoform’s advanced nanoformulation, nanoanalytical, and best-in-class capabilities.

  10. Best-In-Class Nanodevelopment Capabilities 2/3/2025

    Take a tour of Nanoform’s best-in-class nanodevelopment capabilities, setting new standards in innovation. Their highly specialized team excels in creating unique nanoparticles for both small and large molecule APIs.